Comparing the efficacy of botulinum toxin and CGRP antagonists for chronic migraine prophylaxis

Chronic migraines are a neurological disorder, which can be debilitating to patients and result in increased healthcare costs and disability-affected life years. Botox and CGRP antagonists are two drugs used as prophylactic treatments for chronic migraine patients who have failed other medications in the past. However, there are currently no studies that have directly compared the two drugs and existing research indirectly comparing them has had conflicting conclusions regarding efficacy. This double-blind, prospective clinical study aims to determine whether there is a clinically significant difference in efficacy between the two drugs defined as percent reduction in headache days per month. Patients will be recruited and divided into three groups: those who will receive Botox injections, those who will receive Emgality injections, and placebo. The results of this study will be analyzed with ANOVA to determine whether there is a statistically significant difference among the groups, then further analyzed with paired T-tests to determine if one treatment is superior to the other. These results could be used for further research into migraine treatments, as well as to help determine which treatment to trial first in patients with migraines refractory to other medications.

Author dc:creator

• Ly, Phong

Advisors dc:contributor.advisor

• Tzizik, Dan
• Weinstein, John

• Medicine
• Botox
• Botulinum toxin
• CGRP
• CGRP antagonist
• Emgality
• Migraine

Statement dc:rights

• Attribution 4.0 International

Licence dc:rights.uri

• http://creativecommons.org/licenses/by/4.0/

Language dc:language.iso

en_US

Handle dc:identifier.uri

https://hdl.handle.net/2144/49471

OAI identifier oai:identifier

oai:open.bu.edu:2144/49471